Statins for Health & Longevity - Quick Reference Sheet

Statins for Health & Longevity

Created on 10/10/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Statins, inexpensive prescription oral medications that lower blood cholesterol, are used to prevent heart attacks and strokes. The strongest evidence shows fewer heart attacks, strokes and artery-opening procedures, plus a smaller drop in overall deaths. Main harms are a modest blood-sugar rise, mild liver enzyme changes and a small excess of muscle aches. In people over seventy, more years free of dementia or disability were not shown. (Full Review)

Protocol

Intensity by dose
Atorvastatin 10 mg, simvastatin 40 mg or rosuvastatin 5 mg
Lower LDL about 40%; atorvastatin 80 mg about 55%; labeled rosuvastatin range 5–40 mg
Guideline goals
LDL below 100, 70 or 55 mg/dL
Borderline or intermediate, high, and very high risk (2026 ACC/AHA guideline)
Time of day
Simvastatin in the evening; atorvastatin and rosuvastatin at any time
Single daily dose; splitting offers no known advantage
Time to effect
Cardiovascular events
Grows over years
Risk reduction rose from 11% in the first year to 36% after five years
LDL lowering
Within weeks
Can be assessed as early as 4 weeks

Benefits

Contraindications
  • Acute liver failure or decompensated cirrhosis
  • Pregnancy (stop once recognized) and breastfeeding
  • Prior hypersensitivity to the statin, or prior immune-mediated necrotizing myopathy on a statin
  • Simvastatin with strong CYP3A4 inhibitors (itraconazole, ketoconazole, clarithromycin, HIV protease inhibitors), cyclosporine, danazol or gemfibrozil
  • Rosuvastatin above 10 mg in severe renal impairment (creatinine clearance below 30 mL/min/1.73 m², not on hemodialysis)
Key Interactions
  • Macrolide antibiotics (clarithromycin, erythromycin): caution
  • Rosuvastatin with cyclosporine (maximum 5 mg) or gemfibrozil (maximum 10 mg)
  • Calcium-channel blockers and antiarrhythmics (simvastatin maximum 10 mg with verapamil, diltiazem, dronedarone; 20 mg with amiodarone, amlodipine, ranolazine)
  • Colchicine (especially with kidney disease or 1.2 mg/day or more): caution
  • Warfarin: monitor INR
  • Niacin at 1 g/day or more and fibrates (e.g., fenofibrate): caution
  • Aluminum and magnesium hydroxide antacids (rosuvastatin at least 2 hours before)
  • Grapefruit juice: avoid large amounts (more than 1.2 liters daily)
  • Red yeast rice: avoid combining
  • St John's wort: monitor
  • Additive LDL-lowering supplements (psyllium, plant sterols, berberine): monitor
  • Heavy alcohol use: caution
  • Strenuous unaccustomed exercise: caution

Risk & Side Effects

  • High: Muscle symptoms; new-onset diabetes; liver enzyme elevations
  • Medium: Leg swelling
  • Low: Blunted fitness gains from training; kidney and urine changes; cataract; muscle injury and rhabdomyolysis; hemorrhagic stroke; memory and cognitive complaints; sleep, mood and nerve symptoms; headache, nausea and other common complaints; immune-mediated necrotizing myopathy
  • Speculative: CoQ10 depletion; lower testosterone

Monitoring

Marker Target Why
LDL-C Below 100, 70 or 55 mg/dL by risk Main efficacy marker
Non-HDL-C Below 130 or 100 mg/dL by risk Captures all cholesterol in plaque-forming particles
ApoB Below 100, 80 or 65 mg/dL by risk Counts plaque-forming particles directly
Lp(a) Below 125 nmol/L (below 50 mg/dL) Statins raise it modestly
ALT 7–55 U/L Safety check; serious elevation stops use
CK Men 39–308 U/L; women 26–192 U/L Safety check; above 10 times the upper limit with symptoms stops use
HbA1c 4.0–5.6% Safety check; detects statin-related glucose rise
eGFR / creatinine eGFR 60 mL/min/1.73 m² or higher Safety check; low values change dose
TSH 0.4–4.0 mIU/L Safety check; untreated hypothyroidism raises myopathy risk
hs-CRP No established target; track change from own baseline Statins lower it

Cadence: Baseline lipid panel with apoB, one-time Lp(a), liver enzymes, HbA1c, kidney and thyroid function; lipid panel and apoB 4–12 weeks after starting or changing dose, then every 6–12 months; HbA1c at 3–12 months, then yearly; liver enzymes, CK and kidney function only when symptoms or new interacting drugs arise.

Qualitative Assessment

  • Muscle comfort and strength during daily activity and training
  • Exercise capacity and recovery after workouts
  • Energy levels and sleep quality after starting or switching statins
  • Memory and mental clarity, noted alongside timing of any changes
  • Adherence: missed doses and reasons for them